Mineralys Therapeutics Investor Relations Material
Latest events
Q1 2025
Mineralys Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mineralys Therapeutics Inc
Access all reports
Mineralys Therapeutics Inc. (MLYS) is a clinical-stage biopharmaceutical company developing treatments for diseases associated with abnormally elevated aldosterone levels. The company's flagship product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor, currently under investigation for its potential in treating hypertension. The company is headquartered in Radnor, Pennsylvania, and its shares are listed on the Nasdaq.
Key slides for Mineralys Therapeutics Inc
Status Update
Mineralys Therapeutics Inc
KOL Event
Mineralys Therapeutics Inc
Latest articles
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
Ticker symbol
MLYS
Country
🇺🇸 United States